Skip to main content
Equibles
OPRX logo

OPRX · OptimizeRx Corp · Metrics

Track OPRX — free

Use OPRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OPRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.32 -0.05 (-0.53%) At close · Oct 30 Q2 2026 earnings call transcript
Rebalance outlook locked
Customer concentration — top 5 customers 47% of revenue

5 customers — 47% of revenue (the year ended December 31, 2025)

“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”

One customer — 10% of revenue (fiscal 2025)

“one customer that accounted for approximately 10% of total revenue in fiscal 2025 did not generate revenue during the current period, and future revenue from this customer is uncertain.”

3 customers — 10% of revenue (2025)

“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”

5 customers — 49% of revenue (the year ended December 31, 2024)

“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”

2 customers — 10% of revenue (2024)

“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
View the 10-Q filed Aug 13, 2026
Market Cap
$175.55M
Shares
18.84M
Volume · Oct 30 136.55K Avg daily vol (3M) 182.08K

OPRX metrics

104 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.32
Market cap
$175.55M

Price action

20 metrics
Price change (1W)
+1.9%
Price change (30D)
+11.1%
Price change (3M)
+54.0%
Price change (6M)
+39.1%
Price change (YTD)
-24.0%
Price change (1Y)
-52.5%
Trailing year
Price change (5Y)
-90.4%
52-week high
$20.49
52-week low
$4.54
Change from 52-week high
-54.5%
Change from 52-week low
+105.3%
Annualized volatility
69.7%
Annualized volatility (3M)
67.3%
Beta
2.0
RSI (14D)
63.6
Price vs SMA 50
+13.6%
Price vs SMA 200
+27.7%
Avg volume (3M)
182,079
Relative volume
0.8
Average dollar volume
$1.46M

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
18.84M

Valuation

12 metrics
P / E (TTM)
38.8
Trailing earnings · reciprocal yield 2.6%
PEG ratio
—
EV / revenue
1.7×
reciprocal yield 57.6%
EV / EBITDA
11.3×
reciprocal yield 8.9%
EV / EBIT
15.7×
reciprocal yield 6.4%
P / sales
1.8×
reciprocal yield 55.9%
P / book
1.3
reciprocal yield 74.3%
FCF yield
10.4%
TTM · current market cap
Buyback yield
—
P / FCF
9.6
reciprocal yield 10.4%
P / operating cash flow
9.6
reciprocal yield 10.4%
Earnings yield
2.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
712.6×
reciprocal yield 0.1%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 50.6%
EV / revenue historical average (5Y)
2.0×
reciprocal yield 50.6%
EV / EBIT historical average (3Y)
18.9×
reciprocal yield 5.3%
EV / EBIT historical average (5Y)
18.9×
reciprocal yield 5.3%
EV / EBITDA historical average (3Y)
142.1×
reciprocal yield 0.7%
EV / EBITDA historical average (5Y)
142.1×
reciprocal yield 0.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-11
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
73.2%
Operating margin
11.0%
Trailing 12 months
Net margin
4.7%
Gross profit (TTM)
$72.24M
Operating profit (TTM)
$10.90M
Net income (TTM)
$4.60M
Trailing 12 months
Diluted EPS (TTM)
$0.24
FCF margin
18.6%
Effective tax rate
31.8%

Per share

11 metrics
Revenue per diluted share (TTM)
$5.18
Gross profit per diluted share (TTM)
$3.80
Operating profit per diluted share (TTM)
$0.57
EBITDA per diluted share (TTM)
$0.80
Net income per diluted share (TTM)
$0.24
Operating cash flow per diluted share (TTM)
$0.97
Free cash flow per diluted share (TTM)
$0.97
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.42
Book value per share
$6.84

Growth

11 metrics
Revenue growth YoY
-29.8%
Year over year
Net income growth YoY
-145.9%
Revenue (TTM)
$98.65M
Trailing 12 months
EPS growth YoY
-150.0%
Shares change YoY
-1.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+20.6%
Revenue CAGR (5Y)
+20.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+20.8%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
3.5%
Return on assets
2.8%
Debt / equity
0.1
Current ratio
5.6
EBITDA (TTM)
$15.18M
Free cash flow (TTM)
$18.36M
Quick ratio
5.6
Interest coverage
2.3
Net debt / EBITDA
-0.3
Return on invested capital
5.9%
Trailing 12 months
Net cash
$5.09M
Latest balance sheet
Cash & equivalents
$24.10M
Total assets
$164.32M
Total debt
$19.01M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$18.43M
Capital expenditures (TTM)
$77,000
R&D (TTM)
$332,000
SG&A (TTM)
$36.28M
Stock compensation (TTM)
$7.95M
R&D / revenue
—
Stock compensation / revenue
8.1%

Ownership (13F)

9 metrics
13F filers
112
13F filer change QoQ
-18
Institutional ownership
60.3%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
39.6%
Private-fund adviser ownership
37.5%
Active holders' share change QoQ
-7.6%
Holder tenure
10.8
Price vs estimated holder cost
-36.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.2%

Short interest

3 metrics
Short interest
5.7%
Latest settlement · 6.7 days to cover
Days to cover
6.7d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1448431 CUSIP 68401U204 13F (30d) 14 filings 14 filers Visit website Investor relations